COVID-19: Daiichi Sankyo ships AstraZeneca vaccine:
Daiichi Sankyo:
On June 16th, shipment of the new coronavirus vaccine developed by AstraZeneca in the United Kingdom began.
Fill the container with the imported stock solution .
1 million doses through the Japanese government
Supply to Southeast Asia.Japanese goverment:
Approved for AstraZeneca in May.
“The policy of shipping 30 million times overseas” was announced.
Daiichi Sankyo Biotech:
Shipment began on June 15.
This time, we shipped 1 million batches to be supplied to Vietnam.
Since March 2021, the work of filling the vaccine stock solution into a special container called a vial has been underway.
Foreign Minister Toshimitsu Motegi:
Foreign Minister Toshimitsu Motegi announced at a press conference on June 15.
“We will supply vaccines to the next five countries,” he said.
Vietnam,
Indonesia,
Thailand,
Malaysia,
Philippines,AstraZeneca Vaccine:
Unlike US Pfizer and Moderna products, it can be stored refrigerated and is easy to handle.
On the other hand, there have been reports of side reactions that rarely cause thrombosis after inoculation overseas.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXZQOUC161SX0W1A610C2000000/
Tokyo, Japan – (June 16, 2021) –
Daiichi Sankyo Company, Limited
today announced that Daiichi Sankyo Biotech Co., Ltd., has made its shipment of VAXZEVRIATM Intramuscular Injection, a vaccine against novel coronavirus developed by AstraZeneca K.K. .
This shipment of the COVID-19 vaccine is to be provided to Southeast Asian countries and other regions through the Japanese Government.
Under the contract manufacture agreement of the COVID-19 vaccine that Daiichi Sankyo concluded with AstraZeneca in February 2021, Daiichi Sankyo Biotech has engaged in manufacturing the COVID-19 vaccine, including vial filling and packaging, since March of the same year.
The Japanese government
has announced that it will supply 30 million doses of AstraZeneca’s COVID-19 vaccine to various countries and regions through COVAX1 and through other means.
In response to this announcement, a portion of the COVID-19 vaccine to be shipped from Daiichi Sankyo is expected to be provided to countries and regions including Southeast Asian countries through the Japanese Government.
As part of efforts towards ending the global COVID-19 pandemic,
Daiichi Sankyo is striving to support regions in need of medical access through contract manufacture of the COVID-19 vaccine.
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202106/20210616_E.pdf